Siponimod Reduces Disability Progression in Secondary Progressive Multiple Sclerosis
The data from the phase III EXPAND study indicated to the researchers that this risk reduction obtained with siponimod was substantially isolated from MS relapse.
Erenumab Displays Success in Patients Who Failed 2 or More Preventative Migraine Treatments
The calcitonin gene-related peptide inhibitor lowered monthly migraine days by ≥50% in 30.3% of patients compared to 13.7% on placebo.
